BOLOGNA, ROYAL HOTEL CARLTON - October 1-3, 2018 Bologna, Royal Hotel Carlton - Studio ER Congressi
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
PRELIMINARY PROGRAM
President: Pier Luigi Zinzani
Co-President: Michele Cavo
Honorary President: Sante Tura
Bologna,
Royal Hotel Carlton
October 1-3, 2018
BOLOGNA BOLOGNA, ROYAL HOTEL CARLTON
Auspices FACULTY
ALMA MATER STUDIORUM Ranjana Advani Stanford, USA John Kuruvilla Toronto, Canada
UNIVERSITÀ DEGLI STUDI DI BOLOGNA Stephen M. Ansell Rochester, USA Mark Levis Baltimore, USA
Andrea Artoni Milan, Italy Giovanni Martinelli Bologna, Italy
REGIONE EMILIA-ROMAGNA Michele Baccarani Bologna, Italy Anthony R. Mato New York, USA
Andrea Bacigalupo Rome, Italy Philippe Moreau Nantes, France
AZIENDA OSPEDALIERO-UNIVERSITARIA Nizar J. Bahlis Calgary, Canada Alison J. Moskowitz New York, USA
DI BOLOGNA Ivan Borrello Baltimore, USA Craig H. Moskowitz New York, USA
Massimo Breccia Rome, Italy Sattva S. Neelapu Houston, USA
AIL ASSOCIAZIONE ITALIANA CONTRO Tim H. Brummendorf Aachen, Germany Susan M. O’Brien Irvine, USA
LE LEUCEMIE - LINFOMI E MIELOMA Lars Bullinger Berlin, Germany Owen A. O’Connor New York, USA
SEZIONE DI BOLOGNA Christian Buske Ulm, Germany Michinori Ogura Kasugai City, Japan
John Byrd Columbus, USA Fabrizio Pane Naples, Italy
SIE - SOCIETÀ ITALIANA DI EMATOLOGIA Michele Cavo Bologna, Italy Cristina Papayannidis Bologna, Italy
Robert Chen Duarte, USA Francesco Passamonti Varese, Italy
Bruce D. Cheson Washington, USA Ruth Pettengell London, United Kingdom
Paolo Corradini Milan, Italy Vincent Ribrag Villejuif, France
Jorge E. Cortes Houston, USA Paul G. Richardson Boston, USA
Antonio Cuneo Ferrara, Italy Davide Rossi Bellinzona, Switzerland
Ian Flinn Nashville, USA Gianantonio Rosti Bologna, Italy
Robin Foà Rome, Italy Simon Rule Plymouth, United Kingdom
Andres Forero-Torres Birmingham, USA Laurie H. Sehn Vancouver, Canada
Nathan H. Fowler Houston, USA John F. Seymour Melbourne, Australia
Francesco Galimi Thousand Oaks, USA Michele Spina Aviano, Italy
Leo I Gordon Chicago, USA Luis Michael Staudt Bethesda, USA
John Gribben London, United Kingdom Juan Louis Steegmann Madrid, Spain
Claire Harrison London, United Kingdom Constantine Tam Melbourne, Australia
Elias Jabbour Houston, USA Ayalew Tefferi Rochester, USA
Joseph G. Jurcic New York, USA Alessandro M. Vannucchi Florence, Italy
Wojciech Jurczak Kraków, Poland Ravi Vij St. Louis, USA
Jean Jacques Kiladjian Paris, France Umberto Vitolo Turin, Italy
Arne Kolstad Oslo, Norway Anas Younes New York, USA
Marina Konopleva Houston, USA Andrew D. Zelenez New York, USA
Shaji K. Kumar Rochester, USA Pier Luigi Zinzani Bologna, Italy
1
Monday, October 1, 2018
9.00 a.m. Welcome and Introduction
Focus on: Prognostic factor and prediction of
response in lymphoma
Three recent “impressive” stories Chairman: B.D Cheson
Chairman: P. Corradini
2.55 p.m.Molecular predictors of response - L.M. Staudt
9.15 a.m. Checkpoint inhibitors - A. Younes 3.15 p.m. Can we use imaging to predict response? - C.H. Moskowitz
9.40 a.m. Daratumumab - M. Cavo 3.35 p.m. Role of circulating tumor DNA in response prediction and
10.05 a.m. CAR T-cells - S.S. Neelapu assessment of clonal evolution - D. Rossi
Session I: Classical Ph1-neg myeloproliferative neoplasms
SESSION III: Acute leukemia
Chairmen: F. Passamonti, A.M. Vannucchi
Chairmen: M. Levis, G. Martinelli
10.45 a.m. Status of the art of treatment - C. Harrison 4.00 p.m.Status of the art: from genomic knowledge to target
11.05 a.m. Ruxolitinib in myelofibrosis - F. Passamonti therapy in leukemias - L. Bullinger
11.20 a.m. Ruxolitinib in polycitemia vera - A.M. Vannucchi 4.20 p.m. Gliteritinib - M. Levis
11.35 a.m. Interferons in MPNs - J.J. Kiladjian 4.35 p.m. Quizartinib - J.E. Cortes
11.50 a.m. New drugs and combination therapy - A. Tefferi 4.50 p.m. SY-1425 - J.G. Jurcic
12.05 p.m. Allotransplant in myelofibrosis - A. Bacigalupo 5.05 p.m. Inotuzumab in ALL - E. Jabbour
5.20 p.m. Venetoclax - M. Konopleva
12.30 p.m. Lunch
Idasanutlin - C. Papayannidis
5.35 p.m.
Session II: Hodgkin’s lymphoma 5.50 p.m. Ponatinib - E. Jabbour
Chairmen: A. Younes, P.L. Zinzani 6.05 p.m. MCL1 inhibitors - F. Galimi
1.30 p.m. Status of the art of treatment - A. Younes 6.20 p.m. Blinatumumab in Ph+ and
Ph neg ALL - R. Foà
1.50 p.m. Nivolumab - A. Younes
2.05 p.m. Pembrolizumab - R. Chen
2.20 p.m. Brentuximab vedotin - A.J. Moskowitz
2.35 p.m. New Combo-steps - S.M. Ansell
2 3
Tuesday, October 2, 2018
SESSION IV: Non-Hodgkin’s lymphoma (I)
Focus on: “the old, the new and the future in the same drug”
Chairmen: S.M. Ansell, O.A. O’Connor
Chairman: M. Spina
8.30 a.m. Status of the art of treatment - S.M. Ansell 2.15 p.m. Bendamustine - B.D. Cheson
8.50 a.m. Obinutuzumab - L.H. Sehn 2.35 p.m. Lenalidomide - N.H. Fowler
9.05 a.m. MOR208 - W. Jurczak 2.55 p.m. Rituximab biosimilars - C. Buske
9.15 a.m. Polatuzumab - R. Advani 3.15 p.m. Umbralisib (TGR-1202) - A.R. Mato
9.30 a.m. Mogamulizumab - M. Ogura
9.45 a.m. CC-122 - V. Ribrag SESSION VI: Non-Hodgkin’s lymphoma (II)
Chairmen: N.H. Fowler, U. Vitolo
10.00 a.m. EDO-S101 - O.A. O’Connor
10.15 a.m. Selinexor - J. Kuruvilla 3.50 p.m. Venetoclax - S. Rule
10.30 a.m. Pixantrone - R. Pettengell 4.05 p.m. Idelalisib - S.M. Ansell
4.20 p.m. Umbralisib - O.A. O’Connor
11.00 a.m. Coffee break 4.35 p.m. Copanlisib - P.L. Zinzani
Session V: Chronic Lymphocitic Leukemia 4.50 p.m. Duvelisib - I. Flinn
Chairmen: A. Cuneo, R. Foà 5.05 p.m. INCB050465 - A. Forero-Torres
5.20 p.m. ME-401 - A. Zelenetz
11.15 a.m. Status of the art of management - S.M. O’Brien
5.35 p.m. Acalabrutinib - S. Rule
11.35 a.m. Ibrutinib - J. Byrd
5.50 p.m. BGB-3111 - C. Tam
11.50 a.m. Idelalisib - A.D. Zelenez
6.05 p.m. Tazemetostat - V. Ribrag
12.05 p.m. Venetoclax - J. Seymour
6.20 p.m. TAK-659 - L.I. Gordon
12.20 p.m. Acalabrutinib - J. Byrd
6.35 p.m. Betalutin - A. Kolstad
12.35 p.m. BGB-3111 - C. Tam
12.50 p.m. TGR-1202 - J. Gribben
1.15 p.m. Lunch
4 5Wednesday, October 3, 2018
Lecture
8.30 a.m.
Thrombotic thrombocytopenic purpura: a look at the future - A. Artoni
SESSION VII: Multiple myeloma
Chairmen: M. Cavo, P.G. Richardson
8.50 a.m. New proteasome inhibitors (Oprozomib, Marizomib) - P.G. Richardson
9.10 a.m. Selinexor - N. Bahlis
9.30 a.m. Venetoclax - P. Moreau
9.50 a.m. Monoclonal antibodies: Isatuximab, MOR202 - S.K. Kumar
10.10 a.m. Monoclonal antibodies and BTKs: anti-PD-1/PDL-1, Ibrutinib - R. Vij
SESSION VIII: Chronic myeloid leukemia
Chairmen: F. Pane, G. Rosti
10.45 a.m. Bosutinib - T.H. Brummendorf
11.05 a.m. CAR-T and other immunotherapies - I. Borrello
11.20 a.m. Imatinib, nilotinib and dasatinib frontline:
which and why? - J.L. Steegmann
11.35 a.m. ABI001 and combination - M. Breccia
11.50 a.m. Ponatinib - M. Baccarani
12.05 p.m. Treatment free remission - G. Rosti
12.25 p.m. Conclusions and Arrivederci
6 7GENERAL INFORMATION
MEETING VENUE
Royal Hotel Carlton
Via Montebello, 8 - 40121 Bologna, Italy
Phone +39 051 249361 - Fax +39 051 249724
www.royalhotelcarltonbologna.com
OFFICIAL LANGUAGE
English
REGISTRATION FEE
Euro 400,00 (Italian VAT included)
The registration fee includes: conference kit, partecipation in the scientific sessions, attendance certificate,
coffee breaks, lunch, slides of the meeting.
BADGE
All registered participants, speakers and exhibitors will be given a badge which they must wear to be admitted
to the scientific sessions.
ATTENDANCE CERTIFICATE
A certificate will be given to all participants at the end of the meeting.
ITALIAN CME CREDITS
A request for Italian CME credits have been made as follows:
- Provider Studio ER Congressi SRL: ID 828-213626.
- No. 6 CME credits for physicians (disciplines: Allergology and Clinical Immunology, Dermatology and
Venereology, Hematology, Oncology, Pathological Anatomy, Clinical Biochemistry, Clinical Pathology),
biologists and chemists.
- Educational objective: “guidelines-protocols-procedures”.
EUROPEAN CME CREDITS
The program of the “New Drugs in Hematology” has been reviewed and approved for CME accreditation by
the European Board for Accreditation in Hematology (EBAH), an independent accreditation body endorsed
by EHA. The EBAH Unit has approved this educational activity for no. 22 CME credits for Physicians, biolo-
gists and chimists. To request credits, please fill out the form and return it to the registration desk at the end
of the meeting. We remind you that it is necessary to have an EBAH-CME account in order to claim for cre-
dits. Attendees can create an EBAH-CME account registering on the website: http://ebah.org even on site.
CHANGES
Parts of the program may be changed without notice.
8Scientific Secretariat
Pier Luigi Zinzani
Istituto di Ematologia
“Lorenzo e Ariosto Seràgnoli”
Via Massarenti, 9 - 40138 Bologna, Italy
Phone +39 051 6363680 - Fax +39 051 6364037
e-mail: pierluigi.zinzani@unibo.it
Organizing Secretariat
Studio E.R. Congressi
Via Marconi, 36 - 40122 Bologna, Italy
Phone +39 051 4210559 - Fax +39 051 4210174
e-mail: ercongressi@ercongressi.it
www.ercongressi.it
struchel.comYou can also read
